ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronEye IconIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintSite TitleTitle ChevronIcon Twitter
Pharmaceuticals

Pfizer, BioNTech to supply 120m doses of virus vaccine to Japan

Pharma aim to seek regulatory review of drug in October, for delivery in 2021

German biotech company BioNTech and US drugmaker Pfizer began late-stage trials of a coronavirus vaccine this week, which they hope to submit for regulatory review as early as October.   © AP

Pfizer and BioNTech have agreed to supply Japan with 120 million doses of their experimental coronavirus vaccine in the first half of 2021, the companies said on Friday.

The companies did not disclose the financial details of the agreement, but said terms were based on the volume of doses and the timing of the delivery.

The United States has signed a similar deal with Pfizer and BioNTech for 100 million doses for nearly $2 billion, which amounts to a $39 price tag for what is likely to be a two-dose treatment course.

There is no current vaccine for COVID-19. The disease has claimed 670,000 lives and upended economies, and there are over 150 vaccines in various stages of development against the still fast-spreading virus.

German biotech company BioNTech and U.S. drugmaker Pfizer on Monday began a large, late-stage trial of their vaccine candidate to demonstrate its efficacy.

Daiichi Sankyo is in discussions to provide supplies of a potential coronavirus vaccine being developed by AstraZeneca and the University of Oxford for use in Japan.

Assuming clinical success of the vaccines, Pfizer and BioNtech said they were on track to seek regulatory review for the vaccine as early as October.

(Reuters)

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends July 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to the Nikkei Asian Review has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media